Point Therapeutics, Inc. Announces Phase 2 Poster Presentations at Upcoming Scientific Meetings
November 01 2005 - 8:27AM
Business Wire
NSCLC Poster Accepted for Presentation at AACR-NCI-EORTC Conference
and Single Agent Melanoma Poster Accepted for Presentation at iSBTC
Annual Meeting Point Therapeutics, Inc. (NASDAQ: POTP) announced
that it has had posters accepted for presentation at two upcoming
scientific meetings. The company has evaluated additional data from
its Phase 2 trials of talabostat in combination with docetaxel in
metastatic non-small cell lung cancer (NSCLC) and talabostat as a
single agent in metastatic melanoma and intends to present results
at these meetings. In the NSCLC Phase 2 trial, an analysis of all
patients enrolled in the trial showed an increase in median
progression free survival over the previously reported interim
results of 4.0 months. These results further support the company's
recent initiation of its Phase 3 program in metastatic NSCLC
because progression free survival is the primary endpoint in the
Phase 3 program. The additional NSCLC Phase 2 trial results will be
presented in detail at an upcoming poster presentation at the
AACR-NCI-EORTC International Conference on Molecular Targets and
Cancer Therapeutics on Wednesday, November 16, 2005. The company is
also conducting a Phase 2 program, evaluating talabostat in
metastatic melanoma. This program consists of two trials--a single
agent talabostat trial and a combination trial of talabostat with
cisplatin. In the single agent trial, it has been determined that
there are no additional responders beyond those previously
reported. However, the median survival results are generally
consistent with those of the currently approved chemotherapy
standard of care. In addition, talabostat has demonstrated a more
favorable adverse event profile in this study and is orally
administered while the current standard of care is administered
intravenously. The company expects that median survival will be an
important clinical endpoint required for registration. The
additional metastatic melanoma Phase 2 trial results will be
presented in detail at an upcoming poster presentation at the
International Society for the Biological Therapy of Cancer Annual
Meeting on Saturday, November 12, 2005. "We are pleased with the
results from our clinical development programs, including that our
three complete responders--two from our lung cancer trial and one
from our single agent melanoma trial--continue to be complete
responders," said Don Kiepert, President and CEO of Point
Therapeutics, Inc. "In addition to implementing our Phase 3
non-small cell lung cancer program, we continue to evaluate our
Phase 2 metastatic melanoma program and expect to announce by
year-end whether or not we believe the results merit pursuing a
Phase 3 program. It is, however, unlikely that the company would
initiate a Phase 3 metastatic melanoma trial without a partner. We
look forward to presenting updated results at the upcoming
scientific meetings," concluded Kiepert. About Point: Point is a
Boston-based biopharmaceutical company developing a family of
dipeptidyl peptidase (DPP) inhibitors for use in cancer, type 2
diabetes and as vaccine adjuvants. Point is currently studying it
lead product candidate, talabostat, in a Phase 3 trial in NSCLC.
Point is also studying talabostat in several Phase 2 trials,
including as a single agent in metastatic melanoma, in combination
with cisplatin in metastatic melanoma, in combination with
rituximab in advanced chronic lymphocytic leukemia, and in
combination with gemcitabine in metastatic pancreatic cancer. In
addition, Point's portfolio includes two other DPP inhibitors in
preclinical development--PT-630 for type 2 diabetes, and PT-510 as
a vaccine adjuvant. Certain statements contained herein are not
strictly historical and are "forward looking" statements as defined
in the Private Securities Litigation Reform Act of 1995. This
information includes statements with respect to the company's
clinical development programs and the timing of initiation and
completion of its clinical trials. Forward-looking statements are
statements that are not historical facts, and can be identified by,
among other things, the use of forward-looking language, such as
"believes," "feels," "expects," "may," "will," "should," "seeks,"
"plans," "schedule to," "anticipates" or "intends" or the negative
of those terms, or other variations of those terms of comparable
language, or by discussions of strategy or intentions. A number of
important factors could cause actual results to differ materially
from those projected or suggested in the forward looking statement,
including the risk factors described in Point's quarterly report on
Form 10-Q for the quarter ended June 30, 2005 and from time to time
in Point's periodic and other reports filed with the Securities and
Exchange Commission.
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Point Therapeutics (MM) (NASDAQ): 0 recent articles
More Point Therapeutics, Inc. News Articles